Archives
- 2018-07
- 2019-04
- 2019-05
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
We made a number of choices in
2025-02-21
We made a number of choices in the original design of our experiments. First, we used only portions of the 5′ and 3′ regulatory elements from S. cerevisiae. The sequences of these regions were known [32] and our goal was to express the Pf-DHFR at low levels. In fact, our choice of only 600 bp of the
-
In conclusion our study has identified a spl http www
2025-02-21
In conclusion, our study has identified a splice site venlafaxine hydrochloride (c.1769-1G > C) in the AR gene from two patients with complete androgen insensitivity syndrome. The c.1769-1G > C mutation may provide us new insights into the molecular mechanism involved in splicing defects underlying
-
Introduction The burden of cardiovascular disease CVD is und
2025-02-21
Introduction The burden of cardiovascular disease (CVD) is undisputed, accounting for approximately a third of global deaths (17.5 million people in 2012) (WHO, 2012). Atherosclerosis leads to the development of coronary heart disease (CHD) which accounts for more than 40% of these deaths (WHO, 201
-
br STAR Methods br AMPK A Therapeutic Target
2025-02-21
STAR★Methods AMPK: A Therapeutic Target in the β Cell? Loss of pancreatic β cell function is a hallmark of the transition to a diagnosis of T2DM (see Glossary) 1, 2, 3, 4. AMPK activation has gained attention for the treatment of hyperglycemia in prediabetes as an insulin-sensitizing agent bec
-
br Acknowledgements This work was supported by a grant
2025-02-20
Acknowledgements This work was supported by a grant from the National Science Foundation (IOS- 1353366), the Hatch Program of the National Institute of Food and Agriculture (VA-135908) and the Virginia Agricultural Experiment Station, to G.P. Introduction With steadily rising number of affect
-
ALK fusion positive NSCLC is clinically actionable
2025-02-20
ALK fusion-positive NSCLC is clinically actionable because it can be targeted by several FDA-approved drugs, including the first generation TKI crizotinib, which is a dual inhibitor to MET and ALK [15], and the second generation inhibitors, alectinib and ceritinib, both of which are highly-selective
-
It was also shown that of crizotinib resistance mechanisms c
2025-02-20
It was also shown that 15% of crizotinib resistance mechanisms can be due to an amplification of ALK gene while 30% are caused by a variety of secondary mutations (S1206Y, G1202R, L1196M, C1156Y, G1269A, L1152R, F1174L and 1151Tins) in ALK tyrosine kinase. These mutations can modify the conformation
-
Given the powerful and ubiquitous
2025-02-20
Given the powerful and ubiquitous nature of adenosine action within the CNS, basal levels of extracellular adenosine are carefully regulated and are estimated to be in the region of 30–300 nM (Fredholm et al., 2001). The two main pathways for the control of extracellular adenosine involve phosphoryl
-
br Perspectives Given the complexity
2025-02-20
Perspectives Given the complexity of the cellular interactome and of protein scaffolding, further progress in revealing how individual membrane proteins, including APP and AChE, interact with each other at various levels, from cell-surface shedding to gene regulation, will clarify some intrinsic
-
br Difference between ACh and
2025-02-20
Difference between ACh and ER tests There are few reports concerning the provoked spasm between ER and ACh in the same patients [51], [52], [53]. Different mediators may have the potential of different coronary responses. In our experience, spasm provoked by intracoronary injection of ER is focal
-
br Conflict of interest statement
2025-02-20
Conflict of interest statement Benign prostatic hyperplasia (BPH) is a highly complex process characterized by an increased number of epithelial and stromal Auranofin thioredoxin reductase in the transition zone. , , Autopsy studies by McNeal detail the evolution of histological changes within
-
Inhibitors of mPGES are considered as
2025-02-20
Inhibitors of mPGES-1 are considered as safe alternative to NSAIDs in the treatment of chronic inflammatory diseases that are characterized by excessive PGE2 production (Bahia et al., 2014; Khurana and Jachak, 2016; Koeberle et al., 2016; Korotkova and Jakobsson, 2014; Norberg et al., 2013; Psarra e
-
br Cytochrome b br Cytochrome
2025-02-20
Cytochrome b5 Cytochrome P450 17α-hydroxylase/17,20-lyase (P450 17A1) A number of P450s involved in steroid biosynthesis are multifunctional as they carry out two or more sequential hydroxylation reactions on the same substrate(s). P450 17A1 is a dual function endoplasmic reticulum enzyme enco
-
A variety of quinazoline or fused
2025-02-20
A variety of quinazoline or fused pyrimidine-substituted diaminotriazoles showed sub-100nM inhibition of Axl (). Diaminotriazoles similarly substituted with quinolines, isoquinolines and benzothiazoles also showed potent Axl activity (data not shown), but generally exhibited potent cytotoxicity and
-
An AXL decoy receptor with enhanced GAS binding properties
2025-02-20
An AXL decoy receptor with enhanced GAS6-binding properties, MYD1, was engineered as a therapeutic tool to disrupt GAS6/AXL signaling in vivo (Kariolis et al., 2014). MYD1 was shown to block metastasis of human ovarian cancer Z-YVAD-FMK and a murine breast cancer cell line in grafting assays in mic
15916 records 6/1062 page Previous Next First page 上5页 678910 下5页 Last page